CN102309708B - Drug for treating tumor - Google Patents

Drug for treating tumor Download PDF

Info

Publication number
CN102309708B
CN102309708B CN201110266963A CN201110266963A CN102309708B CN 102309708 B CN102309708 B CN 102309708B CN 201110266963 A CN201110266963 A CN 201110266963A CN 201110266963 A CN201110266963 A CN 201110266963A CN 102309708 B CN102309708 B CN 102309708B
Authority
CN
China
Prior art keywords
drug
treating tumor
tumor
chinese
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201110266963A
Other languages
Chinese (zh)
Other versions
CN102309708A (en
Inventor
崔巍
Original Assignee
崔巍
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 崔巍 filed Critical 崔巍
Priority to CN201110266963A priority Critical patent/CN102309708B/en
Publication of CN102309708A publication Critical patent/CN102309708A/en
Application granted granted Critical
Publication of CN102309708B publication Critical patent/CN102309708B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

The invention relates to a drug for treating tumor. The drug for treating tumor is prepared from lophatherum gracile, Chinese paris rhizome, bighead atractylodes rhizome, rhizoma atractylodis, euphorbia lunulata, rheum officinale, balloonflower root, tuber of dwarf lilyturf, Chinese angelica, rhizoma sparganii, Chinese magnoliavine and barbat skullcap. The drug for treating tumor is prepared from the pour traditional Chinese medicines and thus having natural drug characteristics of low toxicity and good curative effects. The drug for treating tumor has clear curative effects and can treat tumor effectively.

Description

A kind of medicament of treating tumor
Technical field
The present invention relates to field of medicaments, specifically, relate to a kind of medicament of treating tumor.
Background technology
Tumor be body under various carcinogenic factor effects, some cells of local organization lose the normal regulation to its growth on gene level, cause its clonal abnormality hypertrophy and the neoplasm that forms.It is generally acknowledged that tumor cell is a monoclonicity, promptly all oncocytes in tumor all are offsprings of the cell of a sudden change.Generally tumor is divided into optimum and pernicious two big types.All malignant tumor are generically and collectively referred to as cancer.
Many clinically at present employing chemicalses are treated, but often the injury for the patient is bigger for chemotherapeutics.
Summary of the invention
The purpose of this invention is to provide a kind of medicament of treating tumor.
In order to realize the object of the invention, the present invention provides a kind of medicament of treating tumor, and it is processed by following bulk drugs by weight:
Preferably, it is processed by following bulk drugs by weight:
Preferably, medicament of the present invention is tablet, dispersible tablet, decoction or capsule.
Medicament of the present invention is prepared with pure Chinese medicine, keeps little, the eutherapeutic characteristic of natural drug toxicity, and curative effect is clear and definite, can treat tumor effectively.
The specific embodiment
Below description through the specific embodiment the present invention is described further; But this is not to be limitation of the present invention; Those skilled in the art are according to basic thought of the present invention; Can make various modifications or improvement, but only otherwise break away from basic thought of the present invention, all within scope of the present invention.
The preparation of embodiment 1 decoction of the present invention
Get Herba Lophatheri 100 gram, Rhizoma Paridis 100 grams, the Rhizoma Atractylodis Macrocephalae 30 grams, Rhizoma Atractylodis 30 grams, Herba euphorbiae lunulatae 100 grams, Radix Et Rhizoma Rhei 50 grams, Radix Platycodonis 50 grams, Radix Ophiopogonis 100 gram, Radix Angelicae Sinensis 50 grams, triangular 50 grams, Fructus Schisandrae Chinensis 100 grams, Herba Scutellariae Barbatae 100 grams; Place 800 ml waters; 90 ℃ of following reflux 3 hours; Filter, obtain filtering residue and filtrating.Said filtrating is concentrated into 300 milliliters, promptly gets.
Experimental example
Be the therapeutic effect that example is investigated medicament of the present invention with pulmonary carcinoma now, this is intended to is schematic and nonrestrictive.
Physical data
40 routine patients with lung cancer all are diagnosed as medium and advanced lung cancer through CT and cytology or pathology.Wherein, male 20 examples, women 20 examples, minimum 44 years old of age, maximum 76 years old, average 60 years old; Classification: scale cancer 19 examples, adenocarcinoma 12 examples, mixed carcinoma 9 examples.Quality of life Ka Shi scoring all>30 minutes.
Take the decoction of preparation among the embodiment 1, three times on the one, each 50 milliliters.60 days is 1 course of treatment.Period in a medicine does not all adopt measures such as any chemotherapy, radiotherapy.
The therapeutic evaluation standard
According to short term effect observation, 2 indexs of appraisal of life quality, observe therapeutic effect.
1. short term effect observe the curative effect standard: according to the objective efficacy assessment standard of WHO treatment of cancer (Chinese Anti-Cancer Association. newly organized common cancer diagnosis and treatment standard primary bronchogenic carcinoma of lung fascicle [S]. Beijing: the .1999:14-26.541. of combined publication society of China Concord Medical Science University of Beijing Medical University); Different by treatment tumor size variation, curative effect is divided into 4 grades.1. alleviate fully: the tumor focus complete obiteration is also kept more than 4 weeks at least; 2. part is alleviated: the product of the maximum gauge of tumor focus and maximum perpendicular transverse diameter dwindles >=and 50%, and keep more than 4 weeks, there is not new focus appearance; 3. stable: two footpath products of swollen lame focus dwindle<and 50%, increase<25%, keep more than 4 weeks, do not have new focus and occur; 4. worsen progress: tumor increases >=25% or new focus occurs.
2. appraisal of life quality: by the Ka Shi standards of grading (look into people person of outstanding talent. modern pulmonary cancer diagnosis and treatment (M) .2 version. Beijing: People's Medical Officer Press .1999:416), rise and 10 be divided into effectively in the treatment back, descends to 10 being divided into invalidly, goes up and down between 10 minutes for stable.
Therapeutic outcome
1. short term effect is observed: alleviate 10 examples fully, part is alleviated 6 examples, stablizes 24 examples, worsens progress 0 example.
2. quality of life treatment back Ka Shi scoring, effective 16 examples of therapeutic effect, therapeutic effect is stablized 24 examples, therapeutic effect 0 example that descends.

Claims (3)

1. medicament of treating pulmonary carcinoma is characterized in that it is processed by following bulk drugs by weight:
2. the medicament of treatment pulmonary carcinoma according to claim 1 is characterized in that, it is processed by following bulk drugs by weight:
3. the medicament of treatment pulmonary carcinoma according to claim 1 and 2 is characterized in that, said medicament is tablet, decoction or capsule.
CN201110266963A 2011-09-09 2011-09-09 Drug for treating tumor Expired - Fee Related CN102309708B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201110266963A CN102309708B (en) 2011-09-09 2011-09-09 Drug for treating tumor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201110266963A CN102309708B (en) 2011-09-09 2011-09-09 Drug for treating tumor

Publications (2)

Publication Number Publication Date
CN102309708A CN102309708A (en) 2012-01-11
CN102309708B true CN102309708B (en) 2012-10-17

Family

ID=45423516

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201110266963A Expired - Fee Related CN102309708B (en) 2011-09-09 2011-09-09 Drug for treating tumor

Country Status (1)

Country Link
CN (1) CN102309708B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102526543B (en) * 2012-03-23 2013-05-29 崔巍 Decoction for treating lung cancer
CN103393743B (en) * 2013-07-10 2015-12-23 聂纪强 A kind of Chinese medicine composition for the treatment of tumor
CN106389546A (en) * 2016-10-18 2017-02-15 漯河医学高等专科学校 Traditional Chinese medicine for postoperative treatment of colorectal cancer and preparation method of traditional Chinese medicine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101829283A (en) * 2009-03-09 2010-09-15 朱敏 Traditional Chinese medicine for treating lung cancer, gastric cancer, bone marrow cancer and metrocarcinoma and preparation method thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101829283A (en) * 2009-03-09 2010-09-15 朱敏 Traditional Chinese medicine for treating lung cancer, gastric cancer, bone marrow cancer and metrocarcinoma and preparation method thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
中药对肺癌细胞增殖与凋亡影响的研究进展;顾后等;《云南中医中药杂志》;20071231;第28卷(第5期);42-44 *
顾后等.中药对肺癌细胞增殖与凋亡影响的研究进展.《云南中医中药杂志》.2007,第28卷(第5期),42-44.

Also Published As

Publication number Publication date
CN102309708A (en) 2012-01-11

Similar Documents

Publication Publication Date Title
CN103039970B (en) A kind of active component and preparation method thereof of nutrient and healthcare products with resist oxygen lack, antifatigue
CN104352608B (en) A kind of benefiting QI for activating blood circulation, hard masses softening and resolving, the Chinese medicine and preparation method thereof of removing toxic substances pain relieving
CN102008650B (en) Compound traditional Chinese medicine preparation for treating tumors and preparation method thereof
CN102309708B (en) Drug for treating tumor
CN102861193B (en) Traditional Chinese medicine composition for treating gastric cancer
CN102284049A (en) Traditional Chinese medicine compound preparation for resisting ulcer and relieving chemoradiotherapeutic toxic and side effects, and preparation method and application thereof
CN102688317B (en) Traditional Chinese medicine for treating liver cancer
CN101804189B (en) Drug for treating primary dysmenorrhea
CN103550718B (en) A kind of Chinese medicine composition for the treatment of pulmonary carcinoma
CN102302719B (en) Medicament for treating tumor
CN104189782A (en) Anti-tumor medicament composition
CN102028924A (en) Medicinal composition for late gastric cancer
CN104524163B (en) A kind of Chinese medicine composition and preparation method for the treatment of chronic bronchitis and merging pulmonary carcinoma
CN106309749A (en) Traditional Chinese medicine for treating cervical cancer
CN108186794B (en) Traditional Chinese medicine composition for treating lung cancer and preparation method and application thereof
CN104888149A (en) Drug for treating cervical cancer and preparation method for drug
CN101979076B (en) Compound combination medicament for treating cerebral metastatic tumor and preparation method and application thereof
CN102038821A (en) Method for preparing medicinal composition for treating dysmenorrhea
CN106138697B (en) Chinese medicinal composition for preventing complications and relieving side effects of radiotherapy and chemotherapy of tumor patients
CN104127532B (en) The application of a kind of NAOXINTONG JIAONANG in preparation treatment oncosis medicine
CN102526543B (en) Decoction for treating lung cancer
CN103599167B (en) A kind of medicament for the treatment of pulmonary carcinoma
CN102836354B (en) Medicament for treating depression
CN101703718A (en) Anti-tumor compound Chinese medicinal preparation
CN102416147B (en) Medicinal composition for treating mania of patients abstained from drugs

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: TIANJIANG PHARMACEUTICAL INDUSTRY CO., LTD., JIANG

Free format text: FORMER OWNER: CUI WEI

Effective date: 20130628

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 273500 JINING, SHANDONG PROVINCE TO: 214400 WUXI, JIANGSU PROVINCE

TR01 Transfer of patent right

Effective date of registration: 20130628

Address after: 214400 Jiangyin Economic Development Zone, Jiangsu, Qin Shan Road, No. 8

Patentee after: Tianjiang Pharmaceutical Industry Co., Ltd., Jiangyin

Address before: 273500 Shandong city of Jining province Guhuai Road No. 79 oncology Affiliated Hospital of Jining Medical College

Patentee before: Cui Wei

TR01 Transfer of patent right

Effective date of registration: 20170420

Address after: Fan Dian Cun 062650 Cangzhou city of Hebei Province, Qingxian County Town, 1 groups of 38, Qingzhou

Patentee after: Wu Jingjing

Address before: 214400 Jiangyin Economic Development Zone, Jiangsu, Qin Shan Road, No. 8

Patentee before: Tianjiang Pharmaceutical Industry Co., Ltd., Jiangyin

TR01 Transfer of patent right
CP02 Change in the address of a patent holder

Address after: Liao LAN Zhen He Jia Dian Lu rock Pingdu City of Qingdao province No. 1 Shandong 266700

Patentee after: Wu Jingjing

Address before: Fan Dian Cun 062650 Cangzhou city of Hebei Province, Qingxian County Town, 1 groups of 38, Qingzhou

Patentee before: Wu Jingjing

CP02 Change in the address of a patent holder
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20121017

Termination date: 20170909

CF01 Termination of patent right due to non-payment of annual fee